Nishioka Hiroshi, Hara Takayuki, Nagata Yuichi, Fukuhara Noriaki, Yamaguchi-Okada Mitsuo, Yamada Shozo
Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Tokyo, Japan; Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
Department of Neurosurgery, Toranomon Hospital, Tokyo, Japan; Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
World Neurosurg. 2017 Oct;106:645-652. doi: 10.1016/j.wneu.2017.07.043. Epub 2017 Jul 19.
Surgical treatment of giant pituitary adenomas is sometimes challenging. We present our surgical series of giant nonfunctioning adenomas to shed light on the limitations of effective and safe tumor resection.
The preoperative tumor characteristics, surgical approaches, outcome, and histology of giant nonfunctioning adenoma (>40 mm) in 128 consecutive surgical patients are reviewed. The follow-up period ranged from 19 to 113 months (mean 62.2 months).
A transsphenoidal approach was used in the treatment of 109 patients and a combined transsphenoidal transcranial approach in 19 patients. A total of 93 patients (72.7%) underwent total resection or subtotal resection apart from the cavernous sinus (CS). The degree of tumor resection, excluding the marked CS invasion, was lower in tumors that were larger (P = 0.0107), showed massive intracranial extension (P = 0.0352), and had an irregular configuration (P = 0.0016). Permanent surgical complications developed in 28 patients (22.0%). Long-term tumor control was achieved in all patients by single surgery, including 43 patients with adjuvant radiotherapy. Most tumors were histologically benign, with a low MIB-1 index (<3.0%) beside a few tumors mainly silent adenomas of pituitary-specific transcription factor lineage.
Irrespective of the surgical approach, massive intracranial extension, an irregular configuration, and marked CS invasion are inherent factors that independently limit effective resection. These high-risk tumors require an individualized therapeutic strategy.
巨大垂体腺瘤的外科治疗有时具有挑战性。我们展示我们的巨大无功能腺瘤手术系列病例,以阐明有效且安全的肿瘤切除的局限性。
回顾128例连续手术患者中巨大无功能腺瘤(>40mm)的术前肿瘤特征、手术入路、结果及组织学情况。随访期为19至113个月(平均62.2个月)。
109例患者采用经蝶窦入路治疗,19例患者采用经蝶窦联合经颅入路治疗。共有93例患者(72.7%)在不包括海绵窦(CS)的情况下接受了全切除或次全切除。在较大的肿瘤(P = 0.0107)、显示有大量颅内扩展的肿瘤(P = 0.0352)以及具有不规则形态的肿瘤(P = 0.0016)中,除明显的CS侵犯外,肿瘤切除程度较低。28例患者(22.0%)出现永久性手术并发症。所有患者通过单次手术实现了长期肿瘤控制,其中43例患者接受了辅助放疗。大多数肿瘤组织学上为良性,MIB-1指数较低(<3.0%),少数肿瘤主要是垂体特异性转录因子谱系的无功能腺瘤。
无论采用何种手术入路,大量颅内扩展、不规则形态和明显的CS侵犯都是独立限制有效切除的内在因素。这些高危肿瘤需要个体化的治疗策略。